Treating Diseases With Protein Modulation

BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis through protein modulation, including protein degradation as well as multi-kinase inhibition, to develop treatments that extend and improve the quality-of-life of patients with life-threatening diseases.

Our principal technology platform centers on targeted protein degradation, as well as PHM® ‘molecular glues’ that enable the design of small molecules to regulate protein equilibrium. This technology utilizes the body’s own protein disposal system to selectively degrade and remove disease-causing proteins. It has potential applicability to a very broad range of disease targets, including those that have to date been considered undruggable.

Latest News

July 28, 2020
BioTheryX Announces $35 Million Series D Financing

March 6, 2020
BioTheryX, Inc. Announces the Appointment of Professor Yinon Ben-Neriah, M.D., Ph.D., to its Scientific Advisory Board

January 16, 2020
BioTheryX Announces the Initiation of Patient Dosing in a First-in-Man Phase 1 Clinical Trial of BTX-A51